Background: The beryllium lymphocyte proliferation test (Be-LPT) measures beryllium-specific cellular immune response, and is useful in medical surveillance of beryllium sensitivity and chronic beryllium disease (CBD).
Methods: Current and former employees (n = 12,194) of 18 United States Department of Energy (DOE) sites were tested for beryllium sensitization at four laboratories with Be-LPT expertise. Beryllium sensitized individuals were offered evaluations for CBD. The sensitivity, specificity, and positive predictive value (PPV) of the Be-LPT were determined, as was inter- and intra-laboratory agreement.
Results: False positives were calculated to be 1.09%, with a laboratory range of 0.00-3.35% for the 10-year investigation. Be-LPTs performed on inter-laboratory split blood specimens from sensitized individuals showed a false negative rate of 31.7%. The intra-laboratory repeatability of abnormal Be-LPT results ranged from 80.4-91.9%. The sensitivity of the Be-LPT was determined to be 0.683, with a specificity of 0.969. The PPV of one abnormal Be-LPT was 0.253.
Conclusions: The Be-LPT is efficacious in medical surveillance of beryllium-exposed individuals. The PPV of the Be-LPT is comparable to other widely accepted medical tests. Confirmation of an abnormal result is recommended to assure appropriate referral for CBD medical evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajim.20082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sarcoidosis in Beryllium Exposed Workers: A Case-Case Study.
Am J Ind Med
January 2025
Division of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Background: Despite the utility of the beryllium lymphocyte proliferation test (BeLPT), distinguishing sarcoidosis, a disease of unknown etiology, from chronic beryllium disease (CBD), has long posed a diagnostic challenge. It is unclear if beryllium-exposed sarcoidosis cases (Be-exp-Sarc) are clinically distinct from CBD, or are misdiagnosed cases of CBD.
Methods: We performed a case-case study of 40 beryllium-exposed individuals diagnosed with Be-exp-Sarc compared to 40 frequency-matched CBD cases.
Multisystemic Beryllium Disease: An Exceptional Case Revealed by a Urinary Tract Granulomatosis.
Int J Mol Sci
July 2024
Department of Nephrology and Dialysis, Brugmann University Hospital, Université libre de Bruxelles, 1020 Bruxelles, Belgium.
Article Synopsis
- Chronic beryllium disease (CBD) is an interstitial lung condition caused by inhaling beryllium particles, and it can often be confused with sarcoidosis but has distinct characteristics and complications.
- A case involving a 60-year-old man revealed multi-organ involvement, with his kidney issues stemming from CBD rather than typical pulmonary symptoms, which were relatively mild.
- The report emphasizes the need for healthcare providers to consider CBD as a potential diagnosis in patients exhibiting granulomatous diseases, especially when they present with related respiratory issues, despite the absence of classical lung symptoms.
Comparing [H] thymidine LPT and CFSE assay to assess lymphocyte proliferation in beryllium-exposed sarcoidosis patients.
Heliyon
September 2023
Laboratory of Toxicology, Unit of Environment & Health, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
The detection of antigen specific lymphocyte responses plays a vital role in the diagnosis of various diseases. Beryllium-specific [H] thymidine lymphocyte proliferation test (LPT) is regarded as a gold standard in identifying chronic beryllium disease (CBD) cases. Alternatively, flow cytometric based carboxyfluorescein succinimidyl ester (CFSE) assay, has several benefits as opposed to LPT, since it further permits both phenotypical characterization and functional analysis of proliferating lymphocyte subsets.
View Article and Find Full Text PDFDifferential diagnosis of pulmonary sarcoidosis: a review.
Front Med (Lausanne)
May 2023
INSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.
Article Synopsis
- Diagnosing pulmonary sarcoidosis is complex due to the lack of specific diagnostic criteria and symptoms that resemble other diseases, making it essential for non-sarcoidosis specialists to have effective differential diagnosis strategies.
- To determine the right diagnosis, a thorough assessment of epidemiological factors, clinical history, and physical examinations, especially chest CT scans, is crucial in identifying which diseases to prioritize for further testing.
- The review highlights the importance of ruling out various alternative granulomatous diseases and conditions through appropriate investigations before confirming a diagnosis of sarcoidosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!